Antimicrobial resistance (AMR) is a significant problem in the treatment of infectious diseases worldwide. This year, the World Health Organization (WHO) published a new list of antimicrobial-resistant bacteria that are considered a priority in terms of research, discovery, and development of new antimicrobials due to their impact on humans, animals, and the environment. The development of new antimicrobials is not fast enough, and it has been observed that resistance to more recent anti-infectives introduced into the clinic is present before their commercial release. The rapid emergence and global spread of multidrug-resistant (MDR) pathogens complicate treatment options, and can result in higher morbidity, mortality, and healthcare costs, highlighting the urgent need for innovative therapeutic approaches and strategies.
Increased efforts to develop new and better therapies and/or strategies for the treatment of pathogens with multiple antimicrobial resistances (MDR) are urgently needed. Global efforts focused on several key areas include robust infection prevention and control (IPC) measures, ensuring equitable access to diagnostics and treatment, surveillance to detect emerging pathogens in AMR, and substantial investment in research and development for the creation of new medicines, diagnostics, and prevention tools.
The goal of this Research Topic is to bring together the most recent and impactful research that addresses these critical areas, offering novel insights and solutions for overcoming the challenges posed by MDR bacteria. We are currently losing this battle, so we aim to accelerate progress towards effective and sustainable strategies capable of curbing the growing threat of AMR and ultimately improving global health outcomes.
Antimicrobial resistance (AMR) is a significant problem in the treatment of infectious diseases worldwide. This year, the World Health Organization (WHO) published a new list of antimicrobial-resistant bacteria that are considered a priority in terms of research, discovery, and development of new antimicrobials due to their impact on humans, animals, and the environment. The development of new antimicrobials is not fast enough, and it has been observed that resistance to more recent anti-infectives introduced into the clinic is present before their commercial release. The rapid emergence and global spread of multidrug-resistant (MDR) pathogens complicate treatment options, and can result in higher morbidity, mortality, and healthcare costs, highlighting the urgent need for innovative therapeutic approaches and strategies.
Increased efforts to develop new and better therapies and/or strategies for the treatment of pathogens with multiple antimicrobial resistances (MDR) are urgently needed. Global efforts focused on several key areas include robust infection prevention and control (IPC) measures, ensuring equitable access to diagnostics and treatment, surveillance to detect emerging pathogens in AMR, and substantial investment in research and development for the creation of new medicines, diagnostics, and prevention tools.
The goal of this Research Topic is to bring together the most recent and impactful research that addresses these critical areas, offering novel insights and solutions for overcoming the challenges posed by MDR bacteria. We are currently losing this battle, so we aim to accelerate progress towards effective and sustainable strategies capable of curbing the growing threat of AMR and ultimately improving global health outcomes.